Sinopharm vaccine(Ain Shams University)(Sinopharm vaccine(Ain Shams University))

概要

基本信息

药物类型

预防性疫苗

别名-

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病

在研适应症-

非在研适应症

新型冠状病毒感染

原研机构

Ain Shams University

在研机构-

非在研机构

Ain Shams University

最高研发阶段无进展临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

6

项与 Sinopharm vaccine(Ain Shams University) 相关的临床试验

IRCT20131221015878N4

/ RecruitingN/AIIT

Immunogenicity and safety of pastocovac vaccine as a booster dose in comparison with sinopharm and pastocovac Plus boosters in Iranian adults aged 18 to 80 who received 2 doses of Sinopharm vaccine: a parallel group clinical trial

开始日期2022-02-26

申办/合作机构-

IRCT20201214049709N4

/ RecruitingN/AIIT

Comparison of immunogenicity and safety of Razi Cov Pars and Sinopharm booster doses in adults 18 years of age and older who have primarily vaccinated with Sinopharm: a ?parallel ??2?? arms, ?randomised, double blind clinical trial ?

开始日期2021-11-30

申办/合作机构

Razi Vaccine & Serum Research Institute

TCTR20210920005

/ Recruiting临床2期IIT

Immunogenicity and safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine in adolescent (age 12-17 years) in Thailand.

开始日期2021-09-14

申办/合作机构-

100 项与 Sinopharm vaccine(Ain Shams University) 相关的临床结果

登录后查看更多信息

100 项与 Sinopharm vaccine(Ain Shams University) 相关的转化医学

登录后查看更多信息

100 项与 Sinopharm vaccine(Ain Shams University) 相关的专利（医药）

登录后查看更多信息

111

项与 Sinopharm vaccine(Ain Shams University) 相关的文献（医药）

2025-01-01·Human Immunology

Evaluation of anti-SARS-CoV-2 RBD antibody response after booster dose of SpikoGen® in individuals with two previous doses of Sinopharm and its association with HLA-DR and -DQ alleles

Article

作者: Hajijafary, Amir Hossein ; Bemani, Peyman ; Feizi, Awat ; Malekmohammad, Somayeh

BACKGROUNDIt has been demonstrated that COVID-19 vaccines confer significant protection, but temporal decay in the vaccine-induced antibodies has been reported; therefore, a third booster dose was considered. Human leukocyte antigen (HLA) class II molecules act as antigen presenting structures, play critical roles in the formation of an efficient antibody response. The current study aimed to evaluate the anti-receptor binding domain (RBD) antibody response after the booster dose of SpikoGen® vaccine in individuals with a history of Sinopharm primary vaccination series and its association with HLA-DQB1 and -DRB alleles.METHODSWhole blood samples were drawn from 95 eligible individuals before and three weeks after the booster dose of SpikoGen®. Quantitative measurement of anti-RBD IgG and qualitative assessment of anti-RBD IgA was performed using the ELISA method and HLA-DQB1 and -DRB loci were genotyped by low-resolution SSP-PCR method.RESULTSA significant increase was observed in the anti-RBD IgG antibodies after the booster dose of SpikoGen® (baseline: 1.82 ± 0.55 GMT, after: 2.28 ± 0.36 GMT)(P < 0.0001). The median fold change of anti-RBD IgG antibodies for DRB1*14 positive individuals (3.96 (1.47-31.75)) was significantly higher than DRB1*14 negative people (1.18 (1.08-1.34))(P = 0.008). In addition, the median fold change of anti-RBD IgG antibodies for DQB1*04 positive individuals (1.39 (1.21-3.43)) was higher than those which were DQB1*04 negative (1.18 (1.08-1.34)), however it was marginally significant (P = 0.060). The seroconversion incidence for anti-RBD IgA antibodies was 68.42 %.CONCLUSIONIn conclusion, our study showed that the booster dose of SpikoGen® can elicit a robust anti-RBD antibody response which was positively associated with DRB1*14 allele.

2024-03-12·Iranian journal of immunology : IJI

Comparative Immunogenicity and Neutralization Potency of Four Approved COVID-19 Vaccines in BALB/c Mice.

Article

作者: Jeddi-Tehrani, Mahmood ; Dashti, Navid ; Amiri, Mohammad Mehdi ; Shokri, Fazel ; Golsaz-Shirazi, Forough ; Zarnani, Amir-Hassan

BackgroundSince the outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), several vaccine candidates have been developed within a short period of time. Although the potency of these vaccines was evaluated individually, their comparative potency was not comprehensively evaluated.ObjectiveTo compare the immunogenicity and neutralization efficacy of four approved COVID-19 vaccines in Iran, including: PastoCovac Plus, Sinopharm, SpikoGen, and Noora in BALB/c mice.MethodsDifferent groups of female BALB/c mice were vaccinated with three doses of each vaccine. The serum levels of antibodies against the viral receptor binding domain (anti-RBD) and spike (anti-spike) protein as well as the vaccine formulation (anti-vaccine) were evaluated using enzyme-linked immunosorbent assay (ELISA). The neutralization efficacy of these four vaccines was assessed through four neutralization assays: conventional virus neutralization test (cVNT), pseudotype virus neutralization test (pVNT), surrogate virus neutralization test (sVNT), and inhibition flow cytometry.ResultsAll four vaccines induced seroconversion in vaccinated animals. All vaccines successfully induced high levels of anti-vaccine antibody; however, PastoCovac Plus and Sinopharm vaccines induced significantly higher levels of anti-RBD antibody titer compared to Noora and SpikoGen. Moreover, the results of the antibody response were corroborated by the virus neutralization tests, which revealed very weak neutralization potency by Noora and SpikoGen in all tests.ConclusionOur results indicate significant immunogenicity and neutralization efficacy induced by PastoCovac Plus and Sinopharm, but not by Noora and SpikoGen. This suggests the need for additional comparative assessment of the potency and efficacy of these four vaccines in vaccinated subjects.

2024-03-02·Cureus

Bilateral Acute Posterior Multifocal Placoid Pigment Epitheliopathy With Bacillary Layer Detachment Following Sinopharm COVID-19 Vaccination: A Case Report

作者: Mahar, P Salim ; Monis, Mohammad Daniyal ; Azam, Muhammad ; Memon, Abdul Sami

Various ocular manifestations associated with COVID-19 and vaccines, affecting both the anterior and posterior segments of the eye have been documented in the literature. In this report, we present the case of a 25-year-old male who complained of sudden-onset blurred vision and metamorphopsia in both eyes one day after receiving the second dose of the Sinopharm COVID-19 vaccine. The visual loss was painless, with no reported flashes or floaters. The patient had no significant medical or surgical history, no history of trauma, and no drug intake. Upon ocular examination, the best-corrected visual acuity was 6/60 (Snellen chart) in both eyes. The anterior segments appeared unremarkable, while fundoscopy revealed multiple yellowish-white subretinal lesions at the posterior pole of both eyes. Spectral domain optical coherence tomography (SD-OCT) confirmed the presence of subretinal fluid (SRF) with neurosensory detachment in each eye, along with bacillary layer detachment (BALAD). There were no signs of inflammation in the vitreous cavity. A diagnosis of acute posterior multifocal plaque pigment epitheliopathy (APMPPE) was established. The patient was prescribed nepafenac 0.1% drops to be instilled three times a day in both eyes and was advised to return for a follow-up examination in two weeks. At the follow-up visit, the patient's vision had improved to 6/9 in the right eye and 6/6 in the left eye, with most of the SRF absorbed. Unilateral APMPPE with BALAD has been mentioned in the literature following various COVID-19 vaccinations, but, to the best of our knowledge, this is the first case report where bilateral APMPPE with BALAD is reported. This case emphasizes the importance of a thorough eye examination for individuals experiencing ocular symptoms after receiving the COVID-19 vaccine.

100 项与 Sinopharm vaccine(Ain Shams University) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床3期	埃及	Ain Shams University	2021-02-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ISTH2022	N/A	凝血障碍	93	Sinopharm covid-19 Vaccine	構壓遞範淵網獵艱憲構(膚齋積選齋鑰糧築鏇壓) = 齋鏇範鹹糧糧憲糧選鹽蓋遞製鏇齋鹽糧鬱鏇餘 (醖觸顧夢憲選鹽獵網膚 )	-	2022-07-09
EHA2022	N/A	血红蛋白病	434	Sinopharm vaccine	夢獵糧獵窪鬱醖餘鏇製(餘艱鑰淵繭築夢廠鑰鏇) = 鑰餘積構觸淵選淵糧觸獵淵顧餘艱憲鏇築憲範 (糧醖構艱衊憲獵蓋憲構 ) 更多	-	2022-06-10
ASCO2022	N/A	肿瘤	177	Pfizer-BioNTech vaccine	願鏇遞構淵鏇遞選顧鑰(糧餘鏇廠糧廠鑰築鑰鑰) = 23 patients (13%) had confirmed COVID-19 infection (post AstraZeneca 1, Pfizer 13, Sinopharm 8, Sinovac 1) 鏇鹽壓繭膚構繭觸繭夢 (膚網鹹齋選鹹夢蓋淵壓 ) 更多	积极	2022-06-02
ASCO2022	N/A	肿瘤	177	Sinopharm (Beijing) vaccine		积极	2022-06-02